Skip to content Skip to sidebar Skip to footer
Subscribe Now
13th Summit on Biosimilars & Innovator Biologics
EVENTS

13th Summit on Biosimilars & Innovator Biologics

The American Conference Institute invites you to attend the 13th Summit on Biosimilars & Innovator Biologics on June 28-29, 2022, back in-person in Boston! Gain government and industry insights on the Innovator and Biosimilars Marketplace from the U.S. FTC, USPTO, AAM, BIO and leading In-House Counsel. We’ve reached an inflection point in the United States. With another major wave of loss…
May 23, 20220Comments

Read more

PharmaShots Interview Biogen’s Monica Mann Shares Insights on the New Real-World Data on Tysabri & Vumerity for the Treatment of Multiple Sclerosis
VIEWPOINTS

PharmaShots Interview: Biogen’s Monica Mann Shares Insights on the New Real-World Data on Tysabri & Vumerity for the Treatment of Multiple Sclerosis

In an interview with PharmaShots, Monica Mann, Vice President, Medical Affairs for Global MS and Pipeline at Biogen shared her views on the data of Tysabri, Vumerity & highlights of new digital health research to predict multiple sclerosis disease progression Shots: Monica spoke about detailed results of the new real-world & clinical data on the long-term use of Tysabri & real-world analyses…
May 17, 20220Comments

Read more

Exclusive_Anita Holz1_Alanna Morris2-2022
EXCLUSIVE

Exclusive Interview with PharmaShots: Anita Holz of Boehringer Ingelheim And Alanna Morris of Emory University Share Insight on Hear Your Heart

In an interview with PharmaShots, Anita Holz, MSN, CRNP, Therapeutic Area Head, Cardiometabolism Medical Affairs, Boehringer Ingelheim & Alanna Morris, Associate Professor of Medicine, Division of Cardiology, Emory University School of Medicine shared their views on the launch of Hear Your Heart to provide resources and education for women with heart failure & highlight inequitable care in black and Latina women Shots: Boehringer &…
May 16, 20220Comments

Read more

PharmaShots Interview GSK’ Angela Carroll Shares Insights on First Paper to Define Disease Modification in Systemic Lupus Erythematosus
VIEWPOINTS

PharmaShots Interview: GSK’ Angela Carroll Shares Insights on First Paper to Define Disease Modification in Systemic Lupus Erythematosus

In an interview with PharmaShots, Angela Carroll, US Medical Affairs Scientific Director-Immuno-inflammation at GSK shared her views on a first published article on disease modification in systemic lupus erythematosus, published in Lupus Science & Medicine Shots: The company has published the first research to define disease modification in SLE including LN in the Lupus Science & Medicine. In multiple therapeutic…
May 11, 20220Comments

Read more

Sign Up to Our Newsletter

Be the first to know the latest updates

[mc4wp_form id="13387" element_id="style-1"]